2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalence
2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volume
2011
Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC
Cohen T, Murray M, Abubakar I, Zhang Z, Sloutsky A, Arteaga F, Chalco K, Franke MF, Becerra MC. Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru - Volume 17, Number 6—June 2011 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2011, 17: 969-975. PMID: 21749756, PMCID: PMC3358204, DOI: 10.3201/eid1706.101471.Peer-Reviewed Original ResearchConceptsMDR-TB patientsMDR-TBMultidrug-resistant tuberculosisTB patientsOptimal treatment regimensMDR Mycobacterium tuberculosisDrug sensitivity testingHigh incidence areaRepetitive unit-variable number tandem repeatHousehold contactsTreatment regimensHousehold transmissionSecondary casesPatientsMycobacterium tuberculosisSensitivity testingCommunity exposureTuberculosisNumber tandem repeatTBSecond strainExposureRegimensSpoligotypingSpontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLOS ONE 2011, 6: e18327. PMID: 21479171, PMCID: PMC3068161, DOI: 10.1371/journal.pone.0018327.Peer-Reviewed Original ResearchConceptsMultiple drug resistanceDrug resistanceInitial treatment regimensTB control programsAnti-TB drugsDrug-resistant formsEmergence of resistanceFunctional monotherapyTreatment regimensCombination therapyTB strainsTuberculosis treatmentTherapy rangeM. tbTB bacilliMultidrug resistanceM. tuberculosisDifferent antibioticsTherapyTuberculosisInfected hostControl programsResistant formsTBMonotherapy
2008
Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study
Cohen T, Colijn C, Finklea B, Wright A, Zignol M, Pym A, Murray M. Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study. PLOS ONE 2008, 3: e2363. PMID: 18523659, PMCID: PMC2408555, DOI: 10.1371/journal.pone.0002363.Peer-Reviewed Original ResearchConceptsResistant tuberculosisIncident casesTotal burdenDrug-resistant TBDrug-resistant tuberculosisSecond-line antibioticsDrug treatment regimensDrug sensitivity testingDrug-resistant strainsBurden of resistanceEmergence of tuberculosisResistant TBTreatment regimensPrevalent casesWorldwide burdenIntroduction of interventionsRoutine surveillanceSurveillance strategiesDrug resistanceTuberculosisLaboratory capacityMycobacterium tuberculosisSensitivity testingTuberculosis modelBurden